The revised world health organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: An alternative proposal

Blood

Volumn 112, Issue 2, 2008, Pages 231-239

  Spivak, Jerry L ^a   Silver, Richard T ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; JANUS KINASE 2;

ARTICLE; BONE MARROW; CLINICAL FEATURE; DIAGNOSTIC TEST; ERYTHROID CELL; GENE MUTATION; HEMATOCRIT; HUMAN; MYELOID METAPLASIA; PLASMA VOLUME; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTOSIS; WORLD HEALTH ORGANIZATION; ALGORITHM; CLASSIFICATION; DIAGNOSIS; MYELOFIBROSIS; PRACTICE GUIDELINE; REVIEW; STANDARD; THROMBOCYTHEMIA;

ALGORITHMS; CLASSIFICATION; DIAGNOSIS; HUMANS; MYELOFIBROSIS; POLYCYTHEMIA VERA; PRACTICE GUIDELINES AS TOPIC; THROMBOCYTHEMIA, HEMORRHAGIC; WORLD HEALTH ORGANIZATION;

EID: 47649121826     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-12-128454     Document Type: Article

References (119)

1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092-1097.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-ofcare diagnostic algorithms. Leukemia. 2008;22: 14-22.
3. World Health Organization. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon. France: IARC Press; 2001.
4. Johansson PL. Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol. 2005;129:701-705.
5. James C. Ugo V. Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434:1144-1148.
6. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365: 1054-1061.
7. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005:352:1779-1790.
8. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
9. Zhao R. Xing S, Li Z. et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788-22792.
10. PikmanY, Lee BH Mercher T. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.
11. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006; 108:3472-3476.
12. Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol. 2007;35:1641-1646.
13. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999;318:593-596.
14. Oosterhuis WP, Bruns DE, Watine J, Sandberg S, Horvath AR. Evidence-based guidelines in laboratory medicine: principles and methods. Clin Chem. 2004;50:806-818.
15. Woolf SH. Do clinical practice guidelines define good medical care? The need for good science and the disclosure of uncertainty when defining "best practices." Chest. 1998;113:166S-171S.
16. Berglund S, Zettervall O. Incidence of polycythemia vera in a defined population. Eur J Haematol. 1992;48:20-26.
17. Taylor KM, Shetta M, Talpaz M, et al. Myeloproliferative disorders: usefulness of X-linked probes in diagnosis. Leukemia. 1989:3:419-422.
18. Janssen JW, Anger BR, Drexler HG, Bartram CR, Heimpel H. Essential thrombocythemia in two sisters originating from different stem cell levels. Blood. 1990;75:1633-1636.
19. Shih LY, Lee CT Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood. 1994;83:744-748.
20. Ellis JT, Peterson P, Geller SA, Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol. 1986; 23:144-155.
21. Barosi G, Cazzola M, Frassoni F, Orlandi E, Stefanelli M. Erythropoiesis in myelofibrosis with myeloid metaplasia: recognition of different classes of patients by erythrokinetics. Br J Haematol. 1981;48:263-272.
22. Cervantes F Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118:786-790.
23. Bouroncle B, Doan CA. Myelofibrosis: clinical, hematologic and pathologic study of 110 patients. Am J Med Sci. 1962;243:697-715.
24. Pitcock JA, Reinhard EH, Justus BW, Mendelsohn RS. A clinical and pathological study of seventy cases of myelofibrosis. Ann Intern Med. 1962;57:73-84.
25. Pettit JE, Lewis SM, Nicholas AW. Transitional myeloproliferative disorder. Br J Haematol. 1979; 43:167-184.
26. Barosi G, Baraldi A, Cazzola M, et al. Polycythaemia following splenectomy in myelofibrosis with myeloid metaplasia: a reorganization of erythropoiesis. Scand J Haematol. 1984;32:12-18.
27. Vaquez LH. Sur une forme spéciale de cyanose s'accompagnant d'hyperglobulie excessive et persistante. C R Soc Biol (Paris). 1892;44:384-388.
28. Osier W. Chronic cyanosis, with polycythemia and enlarged spleen: a new clinical entity. Am J Med Sci. 1903;126:176-201.
29. Wasserman L. The management of polycythemia vera. Br J Haematol. 1971;21:371-376.
30. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130:174-195.
31. McMullin MF, Reilly JT Campbell P, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol. 2007;138:821-822.
32. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost. 1997; 23:339-347.
33. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol. 1999;104:730-737.
34. Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group. Blood. 2002:99:1144.
35. Johansson P, Andreasson B, Safai-Kutti S, et al. On the diagnosis of polycythaemia vera as assessed in the health and medical care in the Vastra Gotaland region, Sweden. J Intern Med. 2002; 251:348-354.
36. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100: 2292-2302.
37. Golde DW, Koeffler HP, Adamson JW. Polycythemia vera: mechanisms and management. Ann Intern Med. 1981;95:71-87.
38. Dupont S, Masse A, James C, etal. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110:1013-1021.
39. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100:4272-4290.
40. Bellanné-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108:346-352.
41. Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood. 2006; 108:3913-3915.
42. Barosi G. Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis and myeloid metaplasia. Blood. 2001:98:3249-3255.
43. Passamonti F, Vanelli L, Malabarba L, et al. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Haematologica. 2003; 88:1123-1129.
44. Pearson TC, Guthrie DL, Simpson J, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol. 1995;89:748-756.
45. Turkington RC, Arnold EC, Percy MJ, et al. Comparison of diagnostic criteria for polycythaemia vera. Hematology. 2007;12:123-130.
46. Wells RE, Merrill EW. Influence of flow properties of blood upon viscosity-hematocrit relationship. J Clin Invest. 1962;41:1591-1598.
47. Pearson TC. Hemorheologic considerations in the pathogenesis of vascular occlusive events in polycythemia vera. Semin Thromb Hemost. 1997; 23:433-439.
48. Freis ED, Stanton JR. Emerson CP. Estimation of relative velocities of plasma and red cells in the circulation of man. Am J Physiol. 1949;157:153-157.
49. Gibson JG, Seligman A, Peacock WC, et al. The distribution of red cells and plasma in large and minute vessels of the normal dog, determined by radioactive isotopes of iron and iodine. J Clin Invest. 1946;848-857.
50. Chaplin H, Mollison P, Vetter H. The body/venous hematocrit ratio: its constancy over a wide hematocrit range. J Clin Invest. 1953;1309-1316.
51. Sánchez C, Merino C, Figallo M. Simultaneous measurement of plasma volume and cell mass in polycythemia of high altitude. J Appl Physiol. 1970;28:775-778.
52. Verel D. Blood volume changes in cyanotic congenital heart disease and polycythemia rubra vera. Circulation. 1961;23:749-753.
53. Weil JV. Jamieson G, Brown DW, et al. The red cell mass-arterial oxygen relationship in normal man. J Clin Invest. 1968;47:1627-1639.
54. Johansson P, Safai-Kutti S, Lindstedt G, Suurkula M, Kutti J. Red cell mass, spleen size and plasma erythropoietin in polycythaemia vera and apparent polycythaemia. Acta Haematol. 2002; 108:1-7.
55. Neff MS, Kim KE, Persoff M, Onesti G, Swartz C. Hemodynamics of uremic anemia. Circulation. 1971;43:876-883.
56. Lamy T, Devillers A, Bernard M, et al. Inapparent polycythemia vera: an unrecognized diagnosis. Am J Med. 1997;102:14-20.
57. Spivak JL, Moliterno AR, Silver RT. Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2. N Engl J Med. 2006:355:737.
58. Hassoun H, Pavlovsky M, Mansoor S, Stopka T Diagnosis of polycythemia vera in an anemic patient. South Med J. 2000;93:710-712.
59. Pearson TC, Botterill CA, Glass UH, Wetherley-Mein G. Interpretation of measured red cell mass and plasma volume in males with elevated venous PCV values. Scand J Haematol. 1984;33: 68-74.
60. Isbister JP. Contracted plasma volume syndromes. Int J Microcirc Clin Exp. 1984;3:93-108.
61. Blum A, Zbar M. Relative polycythemia. Arch Intern Med. 1959:104:385-389.
62. Biswas M, Prakash PK, Cossburn M, Myers K, Hanna F. Life-threatening thrombotic complications of relative polycythaemia. J Intern Med. 2003:253:481-483.
63. Burge PS, Johnson WS, Prankerd TA. Morbidity and mortality in pseudopolycythaemia. Lancet. 1975;1:1266-1269.
64. Bessman DJ. Microcytic polycythemia: frequency of nonthalassemic causes. JAMA. 1977;238: 2391-2392.
65. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304:441-447.
66. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51:189-194.
67. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 1981;58:916-919.
68. Huang LJ, Constantinescu SN, Lodish HF, The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell. 2001;8:1327-1338.
69. Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem. 2005;280:27251-27261.
70. Jones AV, Kreil S. Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-2168.
71. Vizmanos JL, Ormazabal C, Larrayoz MJ, Cross NC, Calasanz MJ. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia. 2006;20: 534-535.
72. Kralovics R. Teo SS, Li S. et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108:1377-1380.
73. Rumi E, Passamonti F, Pietra D, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006;107:2206-2211.
74. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35:32-38.
75. Lacout C, Pisani DF Tulliez M, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108:1652-1660.
76. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840-846.
77. Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia. 2007;21:2210-2212.
78. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2 (V617F) allele burden. Leukemia. 2007;21:1952-1959.
79. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945-1953.
80. Cassinat B, Laguillier C, Gardin C, et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia. 2008;22:452-453.
81. Percy MJ, Jones FG, Green AR, Reilly JT, McMullin M F. The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. Haematologica. 2006;91:413-414.
82. Hand HJ, Laszlo J, Peterson P, et al. Essential thrombocythemia: clinical and laboratory characteristics at presentation. Trans Assoc Am Physicians. 1983;96:165-174.
83. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica. 2000;85:1126-1134.
84. Gianelli U, Vener C, Raviele PR, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma. 2006;47:1774-1781.
85. Tefferi A. Is bone marrow biopsy essential for the diagnosis of essential thrombocythemia? Leuk Lymphoma. 2006;47:1724-1725.
86. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: inter-observer reliability and utility for identifying disease subtypes. Blood. 2008;111:60-70.
87. Cazzola M, Guarnone R, Cerani P, et al. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood. 1998;91:2139-2145.
88. Milledge JS, Cotes PM. Serum erythropoietin in humans at high altitude and its relation to plasma renin. J AppI Physiol. 1985;59:360-364.
89. Singh A, Eckardt KU, Zimmermann A. et al. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest. 1993:91:251-256.
90. Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89:1194-1198.
91. Messinezy M, Westwood NB, El Hemaidi I. et al. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. Br J Haematol. 2002;117:47-53.
92. Casadevall N. Determination of serum erythropoietin: its value in the differential diagnosis of polycythemias. Nouv Rev Fr Hematol. 1994:36:173-176.
93. Prchal JF, Axelrad AA. Bone-marrow responses in polycythemia vera [Letter]. N Engl J Med. 1974;290:1382.
94. Casadevall N, Lacombe C, Varet B. Erythroid cultures and erythropoietin assay: clinical and diagnostic value. Nouv Rev Fr Hematol. 1990;32:77-81.
95. Liu E, Jelinek J, Pastore YD, et al. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2002;101:3294-3301.
96. Zwicky C, Theiler L Zbaren K. Ischi E, Tobler A. The predictive value of clonogenic stem cell assays for the diagnosis of polycythaemia vera. Br J Haematol. 2002;117:598-604.
97. Vannucchi AM, Grossi A, Pancrazzi A, et al. PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. Br J Haematol. 2004;127:214-219.
98. Westwood NB, Pearson TC. Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Leuk Lymphoma. 1996;22(Suppl 1):95-103.
99. Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med. 2003;139:470-475.
100. Berlin Nl. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12:339-351.
101. Najean Y, Rain J. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370-3377.
102. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353:33-45.
103. Bachleitner-Hofmann T Grumbeck E, Gisslinger H. Oral anticoagula nts as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients. Thromb Res. 2003;112:229-232.
104. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656-664.
105. Pearson TC, Weatherly-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 1978;2:1219-1221.
106. 2 transport. J Appl Physiol. 2006;100:482-492.
107. Bagby GC Jr, Richert-Boe K, Koler RD. 32P and acute leukemia: development of leukemia in a patient with hemoglobin Yakima. Blood. 1978;52: 350-354.
108. Najfeld V Price TH, Adamson JW, Fialkow PJ. Myelofibrosis with complex chromosome abnormality in a patient with erythrocytosis due to hemoglobin Rainier and treated with 32P. Am J Hematol. 1978;5:63-69.
109. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006:355:2452-2466.
110. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991; 67:2658-2663.
111. Passamonti F, Rumi E. Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755-761.
112. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275-290.
113. Griesshammer M, Bangerter M, Sauer T, et al. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med. 1999;245:295-300.
114. Buss DH, Cashell AW, O'Connor ML, Richards F, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med. 1994;96:247-253.
115. Mesa RA, Verstovsek S, Cervantes F. et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31:737-740.
116. Thiele J, Kvasnicka HM, Dietrich H, et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol. 2005;20:879-889.
117. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol. 1997; 15:173-189.
118. Varki A, Lottenberg R, Griffith R, Reinhard E. The syndrome of idiopathic myelofibrosis: a clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore). 1983;62:353-371.
119. Videbaek A. Polycythemia vera: course and prognosis. Acta Med Scand. 1950;138:179-187.